Abstract
There is a high degree of morbidity and mortality in fetuses or newborn infants who have been exposed to angiotensin-converting-enzyme (ACE) inhibition during pregnancy.1 Reported complications include oligohydramnios, intrauterine growth retardation, premature labour, fetal and neonatal renal failure, bony malformations, limb contracture, persistent patent ductus arteriosus, pulmonary hypoplasia, respiratory distress syndrome, prolonged hypotension, and neonatal death.2–4 ACE inhibitors are therefore considered to be absolutely contraindicated in pregnant women and it has been suggested that they should not be used in women of child-bearing potential.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
